Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

XenoPort receives grant from Michael J. Fox Foundation to support Parkinson's disease therapies

XenoPort, Inc. announced today that it has been awarded a grant from The Michael J. Fox Foundation for Parkinson's Research to support a preclinical study of the efficacy and safety of a novel, orally administered prodrug of acamprosate in reducing L-Dopa induced dyskinesias (LID) in a pre-clinical model of Parkinson's disease.

24 Nov 2010

FDA clears BG Medicine's Galectin-3 test to identify high risk patients with cardiovascular disease

BG Medicine, Inc., a U.S.-based life sciences company, announced today that the U.S. Food and Drug Administration has cleared the company's Galectin-3 test for use in conjunction with clinical evaluation as an aid to assess the prognosis of patients diagnosed with chronic heart failure. This marks the first time the FDA has cleared a test to measure galectin-3 blood levels, and is the first novel cardiac test cleared by the FDA in five years.

23 Nov 2010

GFAP levels predict brain injury, death in critically ill children on ECMO

Johns Hopkins Children's Center scientists have discovered that high blood levels of a protein commonly found in the central nervous system can predict brain injury and death in critically ill children on a form of life support called extra-corporeal membrane oxygenation or ECMO.

23 Nov 2010

Scientists make breakthrough in techniques for exploring faults in 'smooth' muscles

Clues to the causes of serious, and often fatal, diseases and conditions, such as heart disease, stroke and high blood pressure, are being investigated at the Universities of Strathclyde and Glasgow, both in Scotland, with the use of a -1 million grant.

23 Nov 2010

Arthritis Foundation, Covidien join forces to help Americans suffering from osteoarthritis

The Arthritis Foundation and Covidien have joined forces to help advance awareness and support for millions of people suffering from osteoarthritis in the United States.

23 Nov 2010

Medtronic enters merger agreement to acquire Ardian

Medtronic, Inc. and privately-held Ardian, Inc. announced today that they have entered into a merger agreement whereby Medtronic will acquire Ardian.

22 Nov 2010

Parental divorce during childhood linked to stroke in adulthood

Children who experience a parental divorce are over twice as likely to suffer a stroke at some point in their lives, according to new research presented in New Orleans at The Gerontological Society of America's (GSA) 63rd Annual Scientific Meeting.

22 Nov 2010

Stealth Peptides introduces Bendavia clinical candidate at AHA Scientific Sessions

Stealth Peptides, a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with significant unmet medical needs, introduced its lead clinical candidate, Bendavia, a novel compound that targets the mitochondrion, at the 2010 American Heart Association's (AHA) Scientific Sessions, Resuscitation Science Symposium.

22 Nov 2010

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

SHARP study shows cholesterol-lowering effective for patients with kidney disease

Around a quarter of all heart attacks, strokes, and operations to open blocked arteries could be avoided in people with chronic kidney disease by using the combination of ezetimibe and simvastatin to lower blood cholesterol levels. That's the conclusion from the world's largest ever randomized trial in kidney disease.

22 Nov 2010

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Alexion Pharmaceuticals, Inc. announced today that a Phase 2 clinical study investigating Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy met primary and key secondary endpoints with high levels of statistical and clinical significance, according to results presented today at the American Society of Nephrology (ASN) annual meeting in Denver.

21 Nov 2010

Presence of albumin in urine predicts cognitive decline: Study

A new study has found that low amounts of albumin in the urine, at levels not traditionally considered clinically significant, strongly predict faster cognitive decline in older women.

21 Nov 2010

New editorial dispel doubts about Lou Gehrig's ALS diagnosis

A recent study suggesting that amyotrophic lateral sclerosis (ALS) may be attributed to repetitive head trauma experienced in collision sports lacks scientific epidemiological evidence to support this claim.

20 Nov 2010

Comprehensive guide to current practice of intraoperative neurophysiology

A new book entitled "Intraoperative Neurophysiologic Monitoring" has been published by Cambridge University Press, co-authored by Nationwide Children's Hospital Pediatric Neurologists Gloria M. Galloway, MD, and Khaled M. Zamel, MD; Marc R. Nuwer, MD, of UCLA; and Jaime R. Lopez, MD of Stanford University.

20 Nov 2010

Scientists discover Notch pathway may play a role in alcohol's protective effects

Many studies support the assertion that moderate drinking is beneficial when it comes to cardiovascular health, and for the first time scientists have discovered that a well-known molecule, called Notch, may be behind alcohol's protective effects. Down the road, this finding could help scientists create a new treatment for heart disease that mimics the beneficial influence of modest alcohol consumption.

20 Nov 2010

Vascular Disease Foundation urges diabetic patients to be alert about P.A.D. signs

P.A.D. occurs when arteries in the legs become narrowed or clogged with fatty deposits, reducing blood flow to the legs. This can result in leg muscle pain when walking, disability, amputation, and poor quality of life. Blocked arteries found in people with P.A.D. can be a red flag that other arteries, including those in the heart and brain, may also be blocked - increasing the risk of a heart attack or stroke.

20 Nov 2010

High CRP and low protein albumin levels associated with increased risk of death after PEG-operations

The combination of high CRP and low levels of the protein albumin in the blood, is associated with an increased risk of death after a PEG-operation; implantation of a nutritional catheter into the stomach through the abdominal wall. This was shown in a new study from the Swedish medical university Karolinska Institutet, published in the scientific journal Gastrointestinal Endoscopy. Of the PEG patients in the study that showed both current indicators, 20 percent died within 30 days.

20 Nov 2010

Thorax Institute presents 18-year experience with SynCardia Artificial Heart at Acute Cardiac Care meeting

On Oct. 17, Dr. Jean Christian Roussel from the Thorax Institute at University Hospital of Nantes presented the center's 18-year experience with the SynCardia temporary Total Artificial Heart at the Acute Cardiac Care 2010 medical meeting in Copenhagen, Denmark.

20 Nov 2010

Bristol-Myers Squibb, Pfizer discontinue Phase 3 APPRAISE-2 trial in patients with ACS

Bristol-Myers Squibb Company and Pfizer today reported that the companies have discontinued the Phase 3 APPRAISE-2 clinical trial in patients with recent Acute Coronary Syndrome (ACS) treated with apixaban or placebo in addition to mono or dual antiplatelet therapy.

19 Nov 2010

Study compares effect on HT status in mid, late life on dementia risk

Compared to women never on hormone therapy, those taking hormone therapy only at midlife had a 26 percent decreased risk of dementia; while women taking HT only in late life had a 48 percent increased risk of dementia, according to Kaiser Permanente researchers.

19 Nov 2010

Stroke News and Research

Further Reading

XenoPort receives grant from Michael J. Fox Foundation to support Parkinson's disease therapies

FDA clears BG Medicine's Galectin-3 test to identify high risk patients with cardiovascular disease

GFAP levels predict brain injury, death in critically ill children on ECMO

Scientists make breakthrough in techniques for exploring faults in 'smooth' muscles

Arthritis Foundation, Covidien join forces to help Americans suffering from osteoarthritis

Medtronic enters merger agreement to acquire Ardian

Parental divorce during childhood linked to stroke in adulthood

Stealth Peptides introduces Bendavia clinical candidate at AHA Scientific Sessions

VYTORIN reduces major vascular events in patients with chronic kidney disease

SHARP study shows cholesterol-lowering effective for patients with kidney disease

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Presence of albumin in urine predicts cognitive decline: Study

New editorial dispel doubts about Lou Gehrig's ALS diagnosis

Comprehensive guide to current practice of intraoperative neurophysiology

Scientists discover Notch pathway may play a role in alcohol's protective effects

Vascular Disease Foundation urges diabetic patients to be alert about P.A.D. signs

High CRP and low protein albumin levels associated with increased risk of death after PEG-operations

Thorax Institute presents 18-year experience with SynCardia Artificial Heart at Acute Cardiac Care meeting

Bristol-Myers Squibb, Pfizer discontinue Phase 3 APPRAISE-2 trial in patients with ACS

Study compares effect on HT status in mid, late life on dementia risk

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News